The Private Equity and Public M&A teams advised Novo Holdings in a definitive agreement with Gurnet Point Capital to acquire Paratek Pharmaceuticals (NASDAQ: PRTK). The transaction is valued at approximately $462 million, including the assumption of debt and assuming full payment of a contingent value right.
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation.
Gurnet Point is a leading healthcare fund that invests in de-risked life sciences companies.
Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats.
The Goodwin team was led by Matthew Mauney, Kirkie Maswoswe and Dianna Lee, and included Janet Andolina, Kyle Pine and Ally Gao.
For more details, please read the press release.